Shandong Bailong Chuangyuan Biotechnology Co., Ltd. 2025 First Quarter Results Forecast Announcement

Important notes:

1. The net profit attributable to shareholders of Shandong Bailong Chuangyuan Bio-tech Co., Ltd. (hereinafter referred to as the "Company") in the first quarter of 2025 is expected to increase by RMB 26.4568 million to RMB 31.4568 million compared with the same period last year, a year-on-year increase of 49.41% to 58.75%.

2. After deducting non-recurring gains and losses, the net profit attributable to shareholders of the listed company is expected to increase by RMB 29.0636 million to RMB 34.0636 million compared with the same period last year, a year-on-year increase of 56.71% to 66.47%.

I. Performance forecast for this period

(I) Performance forecast period

January 1, 2025 to March 31, 2025.

(II) Performance forecast

1. According to preliminary calculations by the financial department, the net profit attributable to shareholders of the listed company in the first quarter of 2025 is expected to be RMB 80,000,000-85,000,000, which is expected to increase by RMB 26,456,800-31,456,800 compared with the same period last year, a year-on-year increase of 49.41%-58.75%.

2. The company expects to achieve a net profit attributable to shareholders of the listed company of RMB 80,312,300-85,312,300 after deducting non-recurring gains and losses, which is expected to increase by RMB 29,063,600-34,063,600 compared with the same period last year, a year-on-year increase of 56.71%-66.47%.

(III) The performance forecast for this period is a preliminary forecast of the company based on its operating conditions, and the expected performance has not been audited by a certified public accountant.

2. Performance of the same period last year

(I) Net profit attributable to shareholders of the listed company: RMB 53,543,200. Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses: RMB 51,248,700.

(II) Basic earnings per share: RMB 0.22.

3. Main reasons for the expected increase in performance in this period

(I) Impact of main business

During the reporting period, the main reasons for the expected increase in the company's performance are:

1. The increase in demand from domestic and foreign customers has led to an increase in the company's product sales; 

2. The "30,000 tons of soluble dietary fiber project" and the "15,000 tons of crystalline sugar project" were put into production, and the release of production capacity led to an increase in sales and revenue;

3. The "15,000 tons of crystalline sugar project" was put into production, and the release of production capacity led to an increase in sales and revenue;

4. The commissioning of the "100 tons of crystalline sugar project" has led to a significant reduction in the cost of allulose products, driving the gross profit margin to further increase.

(II) Impact of non-operating gains and losses

Non-recurring gains and losses have no significant impact on the company's current performance forecast.

(III) Impact of accounting treatment

Accounting treatment has no significant impact on the company's current performance forecast.

(IV) Other impacts

The company does not have other factors that have a significant impact on the performance forecast.

IV. Risk warning

This performance forecast is a preliminary calculation made by the company's financial department based on its own professional judgment and has not yet been audited by a certified public accountant. The company does not have any major uncertainties that affect the accuracy of the content of this performance forecast. V. Other matters to note

The above forecast data is only preliminary calculation data. The specific and accurate financial data shall be subject to the company's officially disclosed first quarter report of 2025. Investors are kindly requested to pay attention to investment risks.

This announcement is hereby made.